| US 7,485,661 B2 | ||
| Heterobicyclic pyrazole derivatives as kinase inhibitors | ||
| Roberto Tonani, Novate Milanese (Italy); Simona Bindi, Florence (Italy); Daniele Fancelli, Milan (Italy); Valeria Pittala′, Catania (Italy); and Matteo D'Anello, Novate Milanese (Italy) | ||
| Assigned to Pfizer Italia S.r.l., Roma (Italy) | ||
| Filed on Jan. 18, 2005, as Appl. No. 11/37,986. | ||
| Prior Publication US 2006/0160874 A1, Jul. 20, 2006 | ||
| Int. Cl. A61K 31/4162 (2006.01); C07D 487/02 (2006.01) | ||
| U.S. Cl. 514—406 [548/360.5] | 10 Claims |
1. A bicyclo-pyrazole compound of formula (I):
 X is a group selected from NR′, O, S, SO or SO2;
each of R and R1, being the same or different, is independently selected from hydrogen or an optionally substituted group selected from —R′,
—COR′, —COOR′, —CONHR′, —CONR′R″, —SO2R′, —SO2NHR′ or —SO2NR′R″; wherein each of R′ and R″, being the same or different, is independently selected from hydrogen or an optionally further
substituted straight or branched C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heterocyclyl or aryl-C1-C6 alkyl group;
R2 is an optionally substituted group selected from —R′, —CH2OR′ and OR′, wherein R′ is as above defined;
and the pharmaceutically acceptable salts thereof.
|